38939
document
Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion . INTRODUCTION To evaluate the outcome of cystoid macular edema treated with intravitreal injections of bevacizumab and macular grid laser photocoagulation ( GLP ) , in patients with perfused branch retinal vein occlusion . METHODS Thirty eyes of 30 consecutive patients with cystoid macular edema secondary to nonischemic branch retinal vein occlusion were assigned to either GLP group or to intravitreal bevacizumab ( IB ) group . Complete ophthalmologic examinations were performed just before GLP and IB injection at 1 , 3 , 6 , and 12 months after treatment . Changes in logarithm of minimum angle of resolution ( logMAR ) best-corrected visual acuity ( BCVA ) , central macular thickness ( CMT ) shown by optical coherence tomography-3 were evaluated . RESULTS Baseline BCVA ( logMAR ) and CMT were , respectively , 0.89 +/- 0.13 and 650 +/- 140 microm for the GLP group , 0.87 +/- 0.16 and 690 +/- 120 microm for the IB group . After the treatment , at 1 , 3 , 6 , and 12 months in the GLP group , BCVA had improved by 0.19 , 0.22 , 0.21 , and 0.20 logMAR , CMT had decreased by 40 % , 41.3 % , 40.5 % , and 42 % . In the IB group , BCVA had improved by 0.31 , 0.32 , 0.30 , and 0.31 logMAR and CMT had decreased by 59.5 % , 59 % , 60 % , and 60.3 % . The group receiving bevacizumab had better BCVA and lower CMT values at all time points ( P < 0.05 ) . CONCLUSION Intravitreal bevacizumab injection improves BCVA and reduces CMT more than GLP . Intravitreal bevacizumab injection was well tolerated and could be used as primary treatment in patients with cystoid macular edema secondary to perfused branch retinal vein occlusion .
38940
Intervention_Pharmacological
Bevacizumab
38941
Intervention_Physical
macular laser grid photocoagulation
38942
Intervention_Pharmacological
intravitreal injections of bevacizumab
38943
Intervention_Physical
macular grid laser photocoagulation ( GLP )
38944
Intervention_Physical
GLP
38945
Intervention_Pharmacological
intravitreal bevacizumab ( IB )
38946
Intervention_Physical
GLP
38947
Intervention_Pharmacological
IB
38948
Intervention_Physical
GLP
38949
Intervention_Pharmacological
IB
38950
Intervention_Physical
GLP
38951
Intervention_Pharmacological
IB
38952
Intervention_Pharmacological
bevacizumab
38953
Intervention_Pharmacological
bevacizumab
38954
Intervention_Pharmacological
bevacizumab
38955
Outcome_Physical
Complete ophthalmologic examinations
38956
Outcome_Physical
logarithm of minimum angle of resolution ( logMAR ) best-corrected visual acuity ( BCVA ) , central macular thickness ( CMT ) shown by optical coherence tomography-3
38957
Outcome_Physical
Baseline BCVA ( logMAR ) and CMT
38958
Outcome_Physical
BCVA
38959
Outcome_Physical
CMT
38960
Outcome_Physical
BCVA
38961
Outcome_Physical
logMAR
38962
Outcome_Physical
CMT
38963
Outcome_Physical
BCVA
38964
Outcome_Physical
CMT
38965
Outcome_Physical
BCVA
38966
Outcome_Physical
CMT